Flu vaccine innovation needed to protect children, says GlobalData health care expert
The last time the USA confronted a flu season this early, the virus claimed the lives of nearly 50,000 people nationwide; and, while this year’s spell is not expected to be as damaging as that witnessed in 2003-04, health care analysts from research and consulting firm GlobalData state that a large portion of the population faces an increased risk of infection due to inadequacies in current influenza vaccines.
Brad Tebbets, GlobalData's analyst covering infectious diseases, says that although the existing trivalent influenza vaccines contain viral strains well-matched to the currently circulating influenza A viruses, it is less effective against the influenza B strain.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze